ALK translocation and crizotinib in non-small cell lung cancer: An evolving paradigm in oncology drug development
Open Access
- 9 March 2012
- journal article
- review article
- Published by Elsevier BV in European Journal Of Cancer
- Vol. 48 (7), 961-973
- https://doi.org/10.1016/j.ejca.2012.02.001
Abstract
No abstract availableKeywords
This publication has 79 references indexed in Scilit:
- Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysisThe Lancet Oncology, 2011
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 studyThe Lancet Oncology, 2011
- Biology-Driven Phase II Trials: What Is the Optimal Model for Molecular Selection?Journal of Clinical Oncology, 2011
- ALK Inhibition for Non-Small Cell Lung Cancer: From Discovery to Therapy in Record TimeCancer Cell, 2010
- The biology and treatment of EML4-ALK non-small cell lung cancerEuropean Journal Of Cancer, 2010
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary AdenocarcinomaNew England Journal of Medicine, 2009
- Anaplastic lymphoma kinase: signalling in development and diseaseBiochemical Journal, 2009
- Activating mutations in ALK provide a therapeutic target in neuroblastomaNature, 2008
- Identification of ALK as a major familial neuroblastoma predisposition geneNature, 2008
- Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)The Lancet, 2005